HLA-E and cancer: For instance, antibody-drug conjugates (ADCs) tailored to target precise TAAs bound to HLA-E could capitalize on rapid intracellular internalization, enabling highly effective delivery of potent cytotoxic agents directly into cancer cells, thereby acting as “biological missile” (70).